Report #2894786

Received May 10, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 70 yrs
State: FL
Recovered: Unknown
Vaccinated: Apr 16, 2026
Onset: Apr 1, 2026
Days to onset: —
Hospital days: —

Vaccines (2)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	UNK	—	IM / LA
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	LA

Symptoms (12)

ChillsFatigueFeeling abnormalInjection site massInjection site reactionPain in extremityPruritusPyrexiaRashErythemaIllnessSwelling

Symptom narrative

Redness/red dots on arm; Swelling; Itching; Fever; Sickness; This non-serious case was reported by a consumer via call center representative and described the occurrence of erythema of extremities in a 70-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 16-APR-2026, the patient received the 2nd dose of Shingrix (left arm). In APR-2026, less than 2 weeks after receiving Shingrix, the patient experienced erythema of extremities (Verbatim: Redness/red dots on arm), swelling (Verbatim: Swelling), pruritus (Verbatim: Itching), fever (Verbatim: Fever) and sickness (Verbatim: Sickness). The outcome of the erythema of extremities, swelling, pruritus, fever and sickness were unknown. It was unknown if the reporter considered the erythema of extremities, swelling, pruritus, fever and sickness to be related to Shingrix. It was unknown if the company considered the erythema of extremities, swelling, pruritus, fever and sickness to be related to Shingrix. Additional Information: GSK Receipt Date: 29-APR-2026 The batch number was not provided upon follow up with the reporter.